Hercules Capital Establishes New Private Credit Lending Program for Venture Companies

Hercules Adviser, a wholly-owned subsidiary of Hercules Capital, established a new institutional private credit lending program to support venture and growth stage companies being impacted by recent market events across the venture and growth stage lending ecosystem.

March 27, 2023 Hercules Advisor | Hercules Capital | Scott Bluestein Phil Neuffer

SMBC Increases Hercules Capital’s Letter of Credit Facility to $175MM

Hercules Capital increased its committed letter of credit facility with Sumitomo Mitsui Banking Corporation by $75 million for a total of $175 million in credit capacity, subject to borrowing base, leverage and other restrictions.

March 23, 2023 Hercules Capital | Seth Meyer | Sumitomo Mitsui Banking Corporation Phil Neuffer

Hercules Capital Provides $50MM in Debt Financing to AmplifyBio

AmplifyBio augmented its balance sheet with non-dilutive debt financing, whereby it may borrow a principal amount of up to $50 million from Hercules Capital.

January 13, 2023 AmplifyBio | Bryan Jadot | Hercules Capital | J. Kelly Ganjei Ian Koplin

Silicon Valley Bank and Hercules Capital Provide $300MM Credit Facility to Oak Street Health

Silicon Valley Bank and Hercules Capital provided a $300 million credit facility to Oak Street Health, a network of value-based primary care centers for adults on Medicare. The financing is intended to provide Oak Street Health with operational and strategic capital for the next several years.

November 17, 2022 Hercules Capital | Michael Dutra | Oak Street Health | Silicon Valley Bank | Tim Cook | Tom Hertzberg Ian Koplin

Hercules Capital Provides $125MM Debt Facility to Tricida

Tricida entered into a debt facility with Hercules Capital. The total amount of the debt facility is $125 million of which $100 million will be available for drawdown at Tricida’s option subject to the achievement of certain milestones.

October 20, 2022 Geoff Parker | Hercules Capital | Scott Bluestein | Tricida Ian Koplin

Hercules Capital Provides $200MM Term Loan Facility to Replimune Group

Replimune Group, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, obtained a $200 million non-dilutive term loan facility from Hercules Capital.

October 10, 2022 Armentum Partners | Bryan Jadot | Hercules Capital | Jean Franchi | Replimune Group Ian Koplin

Automation Anywhere Secures $200MM in Financing from Three Banks

Automation Anywhere, a global robotic process automation company, secured $200 million in financing from Silicon Valley Bank, SVB Capital and Hercules Capital. The financing is intended to provide operational and strategic capital for the next several years.

October 4, 2022 Automation Anywhere | Bob Blee | Hercules Capital | James Budge | Mihir Shukla | Silicon Valley Bank Ian Koplin

Hercules Capital Provides $125MM Term Loan Facility to Provention Bio

Provention Bio, a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, secured a term loan facility of up to $125 million with Hercules Capital.

September 1, 2022 Bryan Jadot | Hercules Capital | Jefferies | Provention Bio Ian Koplin

Hercules Capital Enters into $50MM Term Loan Agreement with Alladapt Immunotherapeutics

Alladapt Immunotherapeutics, a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, entered into a term loan agreement for up to $50 million with Hercules Capital.

August 31, 2022 Alladapt Immunotherapeutics | Armentum Partners | Cristy Barnes | Glenn Reicin | Hercules Capital | Himani Bhalla Ian Koplin

Hercules Capital Provides $175MM Term Loan to atai Life Sciences

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, entered into a term loan facility for up to $175 million with Hercules Capital.

August 16, 2022 atai Life Sciences | Hercules Capital | Janice Bourque | Latham & Watkins | Michael Dutra | Morrison & Foerster Ian Koplin